We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 1 Study of the Effect of Ketoconazole on the PK of Multiple Doses of Cediranib in Patients With Solid Tumours

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00750425
First Posted: September 10, 2008
Last Update Posted: March 10, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
  Purpose
Phase I, open study to assess the effect of ketoconazole, a marketed drug, on the way the body handles the experimental drug cediranib, in patients with advanced cancer.

Condition Intervention Phase
Advanced Solid Tumors Drug: cediranib (RECENTIN TM, AZD2171) Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Open Label, Non-Randomised Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Multiple Oral Doses of Cediranib (AZD2171, RECENTINÔ), in Patients With Advanced Solid Tumours

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • To assess the steady-state PK parameters of cediranib in the presence and absence of ketoconazole. [ Time Frame: PK assessments to be taken until Day 42. Days 7 and 10 PK parameters used to assess the primary variables. ]

Secondary Outcome Measures:
  • Safety and tolerability of cediranib in the presence of ketoconazole by assessment of Adverse events (AEs) Laboratory findings,Vital signs, physical examination and Electrocardiogram. [ Time Frame: Until study drug is discountinued ]

Estimated Enrollment: 46
Study Start Date: August 2008
Study Completion Date: January 2011
Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Cediranib alone, followed by cediranib plus ketoconazole, followed by cediranib alone
Drug: cediranib (RECENTIN TM, AZD2171)
20 mg cediranib once daily from Days 1 to 7; then 20 mg cediranib plus 400 mg ketoconazole from Days 8-10; then 20 mg cediranib once daily from Days 11-23. At Day 24 patients may dose escalate to 30 mg tablet once daily providing the treatment is well tolerated (this may be escalated up to 45 mg if the 30mg dose is tolerated for a minimum of 14 days)

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Written informed consent
  • Histological or cytological confirmation of advanced solid tumour (with the exception of prostate cancer), which is refractory to standard therapies or for which no standard therapy exists.
  • Estimated life expectancy of at least 8 weeks
  • WHO performance status (PS) 0-2.

Exclusion Criteria:

  • Unstable brain/meningeal metastases
  • Biochemistry/haematology results outside of required ranges
  • History of significant GI impairment
  • Inadequate bone marrow reserve
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00750425


Locations
Canada
Research Site
Hamilton, Canada
Research Site
Toronto, Canada
Research Site
Vancouver, Canada
Denmark
Research Site
Herlev, Denmark
Research Site
Kobenhavn, Denmark
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Jane Roberston AstraZeneca Aderley Park
Principal Investigator: Dr U Lassen, MD PhD The Finsen Center, Copenhagen, Denmark
  More Information

Responsible Party: Jane Robertson, Medical Science Director, RECENTIN, AstraZeneca
ClinicalTrials.gov Identifier: NCT00750425     History of Changes
Other Study ID Numbers: D8480C00020
EUDRACT number 2008-002271-27
First Submitted: September 8, 2008
First Posted: September 10, 2008
Last Update Posted: March 10, 2011
Last Verified: March 2011

Keywords provided by AstraZeneca:
advanced cancer,
metastatic
ketoconazole
pharmacokinetics
Phase I

Additional relevant MeSH terms:
Ketoconazole
Cediranib
Antifungal Agents
Anti-Infective Agents
14-alpha Demethylase Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Steroid Synthesis Inhibitors
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Cytochrome P-450 CYP3A Inhibitors
Antineoplastic Agents
Protein Kinase Inhibitors